Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

Lynparza First Targeted Therapy Approved for Metastatic Prostate Cancer with HRR Mutation

Web Exclusives - FDA Updates, Prostate Cancer

On May 19, 2020, the FDA approved a new indication for olaparib (Lynparza; AstraZeneca), a PARP inhibitor, for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) and deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) mutation, as identified by an FDA-approved test, whose disease progressed after enzalutamide (Xtandi) or abiraterone acetate (Zytiga) therapy.

Olaparib is the first FDA-approved PARP inhibitor for prostate cancer. The FDA granted olaparib a priority review and a breakthrough therapy designation for this indication.

Olaparib was previously approved for several indications, including different types of ovarian cancer, breast cancer, and pancreatic cancer.

On the same day, the FDA also approved FoundationOne CDx for the identification of patients with mCRPC and HRR mutation, as well as the BRACAnalysis CDx test for the identification of patients with mCRPC and the germline BRCA1 or BRCA2 mutation as companion diagnostic devices for treatment with olaparib.

“Prostate cancer has lagged behind other solid tumors in the era of precision medicine. I am thrilled by the approval of Lynparza, which now brings a new molecular targeted treatment for this patient population,” said Maha Hussain, MD, a principal investigator of the PROfound study and Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University. “The PROfound trial was an international effort and I want to thank the patients, their families, the investigators and their teams involved in making it possible.”

The efficacy of olaparib in prostate cancer was investigated in the PROfound study, an open-label, randomized, multicenter clinical trial. The PROfound study included 387 patients who were randomized in a 2:1 ratio to olaparib 300 mg twice daily (N = 256) or to the investigator’s choice of enzalutamide or abiraterone acetate (N = 131). All patients received a gonadotropin-releasing hormone analog or had previous bilateral orchiectomy.

Patients were divided into 2 cohorts based on their HRR mutation status. Cohort A included patients with BRCA1, BRCA2, or ATM gene mutations (N = 245); group B included patients with any of the 12 HRR gene mutations (N = 142). Patients who had at least 1 mutation of cohort A and 1 mutation of cohort B were included in cohort A.

The primary efficacy outcome was radiologic progression-free survival (PFS) in cohort A. Other efficacy outcomes included objective response rate (ORR) in cohort A, combined radiologic PFS in cohorts A and B, and overall survival (OS) in cohort A.

The median radiologic PFS was significantly longer with olaparib than with the investigator’s choice—7.4 months versus 3.6 months—in cohort A (hazard ratio [HR], 0.34; 95% confidence interval [CI], 0.25-0.47; P <.0001); the median OS was 19.1 months versus 14.7 months, respectively (HR, 0.69; 95% CI, 0.50-0.97; P = .0175); and the ORR was 33% versus 2%, respectively (P <.0001). A significant improvement in radiologic PFS was reported with olaparib versus investigator’s choice in cohorts A and B, with a median of 5.8 months versus 3.5 months, respectively (HR, 0.49; 95% CI, 0.38-0.63; P <.0001).

The most common (≥10%) adverse events with olaparib in the PROfound study were anemia, nausea, fatigue, decreased appetite, diarrhea, vomiting, thrombocytopenia, cough, and dyspnea. The rate of venous thromboembolism (including pulmonary embolism) was 7% with olaparib versus 3.1% with enzalutamide or abiraterone.

The recommended dose of olaparib is 300 mg taken orally twice daily, with or without food.

Related Items
Lumakras First FDA-Approved Therapy for Advanced or Metastatic NSCLC with KRAS G12C Mutation
JHOP - June 2021 Vol 11, No 3 published on June 16, 2021 in FDA Updates
Rybrevant First FDA-Approved Therapy for NSCLC with EGFR Exon 20 Insertion Mutations
JHOP - June 2021 Vol 11, No 3 published on June 16, 2021 in FDA Updates
Zynlonta First FDA-Approved CD19-Directed Therapy for Large B-Cell Lymphoma
JHOP - June 2021 Vol 11, No 3 published on June 16, 2021 in FDA Updates
Jemperli First FDA-Approved Immunotherapy for Advanced Endometrial Cancer with dMMR Biomarker
JHOP - June 2021 Vol 11, No 3 published on June 16, 2021 in FDA Updates
Keytruda Received FDA Approval for First-Line Treatment of HER2-Positive Advanced Gastric Cancer
JHOP - June 2021 Vol 11, No 3 published on June 16, 2021 in FDA Updates
Opdivo First FDA-Approved Immunotherapy for First-Line Treatment of Advanced Gastric Cancer
JHOP - June 2021 Vol 11, No 3 published on June 16, 2021 in FDA Updates
Trodelvy Receives New Indication for Advanced Urothelial Cancer
JHOP - June 2021 Vol 11, No 3 published on June 16, 2021 in FDA Updates
Sarclisa Receives New Indication for Relapsed or Refractory Multiple Myeloma
JHOP - June 2021 Vol 11, No 3 published on June 16, 2021 in FDA Updates
Yescarta First CAR T-Cell Therapy Approved for Follicular Lymphoma
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Lymphoma
Libtayo Receives 2 New Indications: For Basal-Cell Carcinoma and for NSCLC
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Skin Cancer
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.